ID   D-263MG
AC   CVCL_1154
SY   D-263 MG; D263MG
DR   CLO; CLO_0009884
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1154
DR   Cell_Model_Passport; SIDM00732
DR   ChEMBL-Cells; CHEMBL3308255
DR   ChEMBL-Targets; CHEMBL2366183
DR   Cosmic; 946368
DR   Cosmic; 2367514
DR   Cosmic-CLP; 946368
DR   DepMap; ACH-002225
DR   EGA; EGAS00001000978
DR   GDSC; 946368
DR   GEO; GSM1669716
DR   IARC_TP53; 27148
DR   LINCS_LDP; LCL-1371
DR   PharmacoDB; D263MG_272_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1154
DR   Wikidata; Q54817126
RX   DOI=10.1007/0-306-46861-1_11;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=2881426;
RX   PubMed=3011240;
RX   PubMed=3675803;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Problematic cell line: Possibly misidentified. Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 30.77 hours (PubMed=2881426).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu314Asnfs*3 (c.940del); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.41%; Native American=1.08%; East Asian, North=0.75%; East Asian, South=0%; South Asian=2.84%; European, North=63.92%; European, South=31.01% (PubMed=30894373).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 14
ST   D16S539: 11,12
ST   D5S818: 11
ST   D7S820: 10
ST   TH01: 8,9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In) Human cell culture. Vol. 2. Cancer Cell Lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994).
//
RX   PubMed=2881426; DOI=10.1007/BF00687952;
RA   Bigner S.H., Friedman H.S., Biegel J.A., Wikstrand C.J., Mark J.,
RA   Gebhardt R., Eng L.F., Bigner D.D.;
RT   "Specific chromosomal abnormalities characterize four established cell
RT   lines derived from malignant human gliomas.";
RL   Acta Neuropathol. 72:86-97(1986).
//
RX   PubMed=3011240; DOI=10.1016/0165-4608(86)90172-X;
RA   Bigner S.H., Mark J., Bullard D.E., Mahaley M.S. Jr., Bigner D.D.;
RT   "Chromosomal evolution in malignant human gliomas starts with specific
RT   and usually numerical deviations.";
RL   Cancer Genet. Cytogenet. 22:121-135(1986).
//
RX   PubMed=3675803;
RA   Bigner S.H., Bjerkvig R., Laerum O.D., Muhlbaier L.H., Bigner D.D.;
RT   "DNA content and chromosomes in permanent cultured cell lines derived
RT   from malignant human gliomas.";
RL   Anal. Quant. Cytol. Histol. 9:435-444(1987).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//